Biomarkers and transcriptome profiling of lung cancer

Respirology

Volumn 17, Issue 4, 2012, Pages 620-626

  Chen, Hsuan Yu ^a   Yu, Sung Liang ^b   Li, Ker Chau ^a   Yang, Pan Chyr ^c  

^a INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

epidermal growth factor receptor; liquid association; lung cancer; microarray; microRNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; SINGLE STRANDED RNA; TRANSCRIPTOME; TUMOR MARKER;

CANCER PATIENT; CELL PROLIFERATION; DISEASE MARKER; DNA FINGERPRINTING; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTOME PROFILING;

BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG NEOPLASMS; MICRORNAS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS;

EID: 84859926119     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02154.x     Document Type: Review

References (80)

1. Jemal A, Siegel R, Xu J, et al,. Cancer Statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Parkin DM, Bray FI, Devesa SS,. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001; 37: S4-66.
3. Hoffman PC, Mauer AM, Vokes EE,. Lung cancer. Lancet 2000; 355: 479-85. (Pubitemid 30085163)
4. Mountain CF,. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-17. (Pubitemid 27260107)
5. Naruke T, Goya T, Tsuchiya R, et al,. Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg. 1988; 96: 440-7.
6. Ludwig JA, Weinstein JN,. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005; 5: 845-56. (Pubitemid 41746029)
7. Sidransky D,. Emerging molecular markers of cancer. Nat. Rev. Cancer 2002; 2: 210-19. (Pubitemid 37328790)
8. Etzioni R, Penson DF, Legler JM, et al,. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J. Natl Cancer Inst. 2002; 94: 981-90. (Pubitemid 34814727)
9. Vastag B,. Study concludes that moderate PSA levels are unrelated to prostate cancer outcomes. JAMA 2002; 287: 969-70. (Pubitemid 34252043)
10. Esquela-Kerscher A, Slack FJ,. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006; 6: 259-69.
11. Yu SL, Chen HY, Chang GC, et al,. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008; 13: 48-57.
12. Chen H-Y, Yu S-L, Chen C-H, et al,. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 2007; 356: 11-20. (Pubitemid 46041749)
13. Weir BA, Woo MS, Getz G, et al,. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-8. (Pubitemid 350231325)
14. Redon R, Ishikawa S, Fitch KR, et al,. Global variation in copy number in the human genome. Nature 2006; 444: 444-54. (Pubitemid 44809057)
15. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.
16. Schena M, Shalon D, Davis RW, et al,. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70.
17. Schena M, Shalon D, Heller R, et al,. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc. Natl Acad. Sci. U. S. A. 1996; 93: 10614-19. (Pubitemid 26333036)
18. Hoheisel JD,. Microarray technology: beyond transcript profiling and genotype analysis. Nat. Rev. Genet. 2006; 7: 200-10. (Pubitemid 43361531)
19. Golub TR, Slonim DK, Tamayo P, et al,. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-7.
20. Ramaswamy S, Ross KN, Lander ES, et al,. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003; 33: 49-54. (Pubitemid 36068681)
21. Beer DG, Kardia SL, Huang CC, et al,. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002; 8: 816-24.
22. Bhattacharjee A, Richards WG, Staunton J, et al,. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. U. S. A. 2001; 98: 13790-5. (Pubitemid 33115977)
23. Garber ME, Troyanskaya OG, Schluens K, et al,. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. U. S. A. 2001; 98: 13784-9. (Pubitemid 33115976)
24. Wigle DA, Jurisica I, Radulovich N, et al,. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002; 62: 3005-8. (Pubitemid 34602385)
25. Gordon GJ, Jensen RV, Hsiao L-L, et al,. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002; 62: 4963-7. (Pubitemid 34984420)
26. Shedden K, Taylor JMG, Enkemann SA, et al,. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 2008; 14: 822-7.
27. Ramaswamy S,. Translating cancer genomics into clinical oncology. N. Engl. J. Med. 2004; 350: 1814-16. (Pubitemid 38917246)
28. Endoh H, Tomida S, Yatabe Y, et al,. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J. Clin. Oncol. 2004; 22: 811-19. (Pubitemid 41103592)
29. Hsu Y-C, Yuan S, Chen H-Y, et al,. A four-gene signature from NCI-60 cell line for survival prediction in non small cell lung cancer. Clin. Cancer Res. 2009; 15: 7309-15.
30. Hammond SM,. MicroRNAs as oncogenes. Curr. Opin. Genet. Dev. 2006; 16: 4-9. (Pubitemid 43089605)
31. Calin GA, Croce CM,. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006; 66: 7390-4. (Pubitemid 44289189)
32. He L, Hannon GJ,. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004; 5: 522-31. (Pubitemid 38868508)
33. Volinia S, Calin GA, Liu CG, et al,. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. U. S. A. 2006; 103: 2257-61. (Pubitemid 43271657)
34. Calin GA, Ferracin M, Cimmino A, et al,. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005; 353: 1793-801. (Pubitemid 41549891)
35. Iorio MV, Ferracin M, Liu CG, et al,. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65: 7065-70. (Pubitemid 41161233)
36. Roldo C, Missiaglia E, Hagan JP, et al,. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006; 24: 4677-8.
37. Takamizawa J, Konishi H, Yanagisawa K, et al,. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64: 3753-6. (Pubitemid 38697282)
38. Lossos IS, Czerwinski DK, Alizadeh AA, et al,. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 2004; 350: 1828-37. (Pubitemid 38917249)
39. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006; 6: 857-66. (Pubitemid 44629897)
40. Simon R, Radmacher MD, Dobbin K, et al,. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 2003; 95: 14-18. (Pubitemid 36124291)
41. Pepe MS, Janes H, Longton G, et al,. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 2004; 159: 882-90. (Pubitemid 38657490)
42. Ware JH,. The limitations of risk factors as prognostic tools. N. Engl. J. Med. 2006; 355: 2615-17. (Pubitemid 44969120)
43. Wang TJ, Gona P, Larson MG, et al,. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 2006; 355: 2631-9. (Pubitemid 44969122)
44. Bogdan S, Klambt C,. Epidermal growth factor receptor signaling. Curr. Biol. 2001; 11: R292-5. (Pubitemid 32324746)
45. Cohen S,. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem. 1962; 237: 1555-62.
46. Brabender J, Danenberg KD, Metzger R, et al,. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 2001; 7: 1850-5. (Pubitemid 32994816)
47. Herbst RS, Maddox AM, Rothenberg ML, et al,. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 2002; 20: 3815-25.
48. Mendelsohn J,. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 2000; 6: 747-53. (Pubitemid 30159326)
49. Yarden Y, Ullrich A,. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 1988; 57: 443-78.
50. Politi K, Zakowski M, Fan P, et al,. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006; 20: 1496-510. (Pubitemid 43830656)
51. Ding L, Getz G, Wheeler DA, et al,. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
52. Fukuoka M, Yano S, Giaccone G, et al,. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003; 21: 2237-46. (Pubitemid 46621858)
53. Kris MG, Natale RB, Herbst RS, et al,. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58. (Pubitemid 37432975)
54. Mohamed MK, Ramalingam S, Lin Y, et al,. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann. Oncol. 2005; 16: 780-5. (Pubitemid 40767100)
55. Perez-Soler R, Chachoua A, Hammond LA, et al,. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004; 22: 3238-47. (Pubitemid 41103678)
56. Shih JY, Gow CH, Yu CJ, et al,. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int. J. Cancer 2006; 118: 963-9.
57. Lynch TJ, Bell DW, Sordella R, et al,. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-39. (Pubitemid 38637993)
58. Paez JG, Janne PA, Lee JC, et al,. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. (Pubitemid 38720929)
59. Pao W, Miller V, Zakowski M, et al,. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. U. S. A. 2004; 101: 13306-11. (Pubitemid 39209661)
60. Mok TS, Wu Y-L, Thongprasert S, et al,. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-57.
61. Huang SF, Liu HP, Li LH, et al,. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 2004; 10: 8195-203.
62. Kosaka T, Yatabe Y, Endoh H, et al,. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004; 64: 8919-23. (Pubitemid 39665498)
63. Shigematsu H, Lin L, Takahashi T, et al,. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 2005; 97: 339-46. (Pubitemid 40425952)
64. Janne PA, Johnson BE,. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 2006; 12: 4416s-20s. (Pubitemid 44197191)
65. Mitsudomi T, Kosaka T, Endoh H, et al,. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005; 23: 2513-20. (Pubitemid 47050841)
66. Sordella R, Bell DW, Haber DA, et al,. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-7. (Pubitemid 39100331)
67. Ono M, Hirata A, Kometani T, et al,. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004; 3: 465-72. (Pubitemid 39193724)
68. Inoue A, Suzuki T, Fukuhara T, et al,. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 2006; 24: 3340-6. (Pubitemid 46638887)
69. Mitsudomi T, Morita S, Yatabe Y, et al,. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-8.
70. Han SW, Kim TY, Hwang PG, et al,. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 2005; 23: 2493-501.
71. Takano T, Ohe Y, Sakamoto H, et al,. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005; 23: 6829-37.
72. Yun CH, Boggon TJ, Li Y, et al,. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007; 11: 217-27. (Pubitemid 46349842)
73. Kobayashi S, Boggon TJ, Dayaram T, et al,. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005; 352: 786-92. (Pubitemid 40271173)
74. Pao W, Miller VA, Politi KA, et al,. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2: e73.
75. Shih JY, Gow CH, Yang PC,. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N. Engl. J. Med. 2005; 353: 207-8.
76. Rosell R, Moran T, Queralt C, et al,. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009; 361: 958-67.
77. Yuan S, Yu S-L, Chen H-Y, et al,. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J. Clin. Oncol. 2011; 29: 3435-42.
78. Li K-C,. Genome-wide coexpression dynamics: theory and application. Proc. Natl Acad. Sci. U. S. A. 2002; 99: 16875-80. (Pubitemid 36034066)
79. Li K-C, Liu C-T, Sun W, et al,. A system for enhancing genome-wide coexpression dynamics study. Proc. Natl Acad. Sci. U. S. A. 2004; 101: 15561-6. (Pubitemid 39473527)
80. Li K-C, Palotie A, Yuan S, et al,. Finding disease candidate genes by liquid association. Genome Biol. 2007; 8: R205.